HUTCHMED (China) Limited (HKG:0013)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
24.85
+0.60 (2.47%)
Apr 24, 2025, 4:08 PM HKT

HUTCHMED (China) Company Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.

The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.

It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).

In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML.

It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.

HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited
Country Cayman Islands
Founded 2000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,811
CEO Wei-Guo Su

Contact Details

Address:
Cheung Kong Center
Hong Kong
Hong Kong
Phone 852 2121 8200
Website hutch-med.com

Stock Details

Ticker Symbol 0013
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number KYG4672N1198
SIC Code 2834

Key Executives

Name Position
Dr. Wei-Guo Su B.Sc., Ph.D. Chief Executive Officer, Chief Scientific Officer and Executive Director
Chig Fung Cheng BEc, CA Chief Financial Officer and Executive Director
Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E Company Secretary and Non-Executive Director
Yiling Cui Executive Vice President and Head of Operations
David Ng Head of Investor Relations and Capital Strategies
Charles George Rupert Nixon Group General Counsel
Kin Hung Lee M.B.A. Senior Vice President of Corporate Management and Communications
Selina Zhang Senior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D. Executive Vice President of Business Development and Strategic Alliances
Dr. Zhenping Wu M.B.A, Ph.D. Executive Vice President of Pharmaceutical Science and Manufacturing